Breaking the Cycle of Non-Healing Diabetic Ulcers: Multifunctional Aerogel Dressing Offers a Comprehensive Therapeutic Strategy

Chronic wounds, such as diabetic foot ulcers, represent one of the most formidable complications for diabetic patients. Their treatment is hindered by a vicious pathological cycle: the hyperglycemic environment not only directly damages cells but also triggers persistent oxidative stress and chronic inflammation. Excessive reactive oxygen species (ROS) destroy nascent tissue, while a dysregulated immune response fails to clear pathogens effectively and instead releases a barrage of pro-inflammatory cytokines, further impeding angiogenesis and collagen deposition. Conventional dressings often merely act as passive absorbers or physical barriers, unable to actively intervene in this core pathophysiological process. Therefore, there is an urgent need in the fields of biomaterials and regenerative medicine to develop an intelligent dressing capable of synergistically combating oxidative stress, suppressing infection, and actively promoting tissue regeneration.

Recently, a groundbreaking study published in a premier journal has offered a highly promising solution to this challenge: a multifunctional aerogel dressing named CeO₂@NMN/SA. This research not only demonstrates its exceptional therapeutic efficacy both in vitro and in vivo but also delves deep into its sophisticated molecular mechanism: the systemic regulation of the diabetic wound microenvironment through targeted activation of the crucial longevity protein, the Sirt1 signaling pathway.

Innovative Design: Integration of Triple Functions

The core innovation of this study lies in the ingenious design of the material. The researchers skillfully integrated three components with complementary functions into a single sodium alginate (SA) aerogel matrix:

1. Nanozyme CeO₂ (Cerium dioxide): Acting as a biomimetic catalyst, CeO₂ nanoparticles possess a unique redox cycling capability (Ce³⁺ ⇌ Ce⁴⁺), enabling them to function like superoxide dismutase (SOD) and catalase (CAT). They can efficiently and persistently scavenge harmful ROS, such as superoxide anion (O₂⁻) and hydrogen peroxide (H₂O₂), from the wound site, thereby breaking the cycle of oxidative stress.
2. NMN (β-Nicotinamide Mononucleotide): This is a direct precursor to NAD⁺, a vital coenzyme within cells. Under diabetic conditions, intracellular NAD⁺ levels are significantly depleted, leading to reduced activity of Sirt1, an NAD⁺-dependent deacetylase. Sirt1 is a key "longevity protein" that regulates cellular metabolism, antioxidant defense, anti-inflammation, and survival. By delivering NMN, the dressing can effectively boost intracellular NAD⁺ levels, thereby reactivating the Sirt1 pathway.
3. SA Aerogel Matrix (Sodium Alginate): The three-dimensional porous network structure formed by this natural polysaccharide serves as an ideal carrier for CeO₂ and NMN. It also offers excellent water absorption, biocompatibility, and biodegradability, creating a moist and breathable microenvironment for the wound that degrades gradually as healing progresses, avoiding secondary trauma.

This "nanozyme + metabolic modulator + smart carrier" triad design empowers the CeO₂@NMN/SA aerogel to act on diabetic wounds from multiple dimensions simultaneously.

Exceptional Efficacy: Accelerating the Wound Repair Process

The research team comprehensively validated the therapeutic potential of this dressing through a series of rigorous in vitro and in vivo experiments.

• Potent Antibacterial & Anti-Biofilm Activity: In vitro tests showed that CeO₂@NMN/SA exhibited significant inhibitory effects against common wound pathogens (e.g., S. aureus and E. coli) and could effectively disrupt pre-formed bacterial biofilms, clearing a major obstacle to healing.
• Superior In Vivo Healing Outcomes: In a full-thickness skin defect model in diabetic mice, the CeO₂@NMN/SA treatment group demonstrated remarkable healing rates. Compared to blank controls, single-component groups (e.g., dressings containing only CeO₂ or NMN), and a clinical positive control, its wound closure rate was the highest by day 14. Histological analysis (H&E staining) confirmed that the dressing significantly promoted granulation tissue formation and re-epithelialization.
• Promotion of Angiogenesis and Cell Proliferation: Immunohistochemical staining (for CD31 and Ki67) revealed that the density of new blood vessels and the number of proliferating cells in the wound tissue of the CeO₂@NMN/SA group were significantly higher than in other groups, indicating successful activation of the tissue regeneration program.
• Creation of an Anti-inflammatory & Pro-reparative Microenvironment: ELISA assays indicated that the dressing effectively downregulated the expression of the pro-inflammatory cytokine IL-6 while upregulating the anti-inflammatory cytokine IL-10, successfully shifting the wound from a state of chronic inflammation to one conducive to repair. Furthermore, Masson’s trichrome staining clearly showed that the treated group had richer and more orderly arranged collagen fiber deposition, providing a solid structural foundation for new tissue.

Mechanistic Insight: The Pivotal Role of the Sirt1 Pathway

The most profound contribution of this study is the elucidation of the core molecular mechanism behind the therapeutic effects of CeO₂@NMN/SA. The researchers discovered that whether it was CeO₂ scavenging ROS or NMN replenishing NAD⁺, their ultimate convergent effect was the activation of the Sirt1 protein.

• Elevated NAD⁺ Levels: In human umbilical vein endothelial cells (HUVECs) and human keratinocytes (HaCaT), treatment with CeO₂@NMN/SA significantly increased intracellular NAD⁺ levels.
• Activation of the Sirt1 Pathway: Western Blot analysis confirmed that after treatment with the dressing, the expression of Sirt1 protein and its key downstream effectors, Nrf2 (Nuclear factor erythroid 2–related factor 2) and HO-1 (Heme oxygenase-1), were all significantly upregulated. The Nrf2/HO-1 axis is one of the most critical intracellular antioxidant defense pathways.
• Functional Validation: To confirm the central role of Sirt1, the researchers used EX527, a specific Sirt1 inhibitor. When EX527 was added, the antioxidant, anti-inflammatory, and pro-angiogenic effects of CeO₂@NMN/SA were significantly diminished or even completely blocked. This "loss-of-function" experiment provides irrefutable evidence that the Sirt1 pathway is the master switch for the multifaceted therapeutic effects of this dressing.

Conclusion and Outlook: An Intelligent Dressing on the Path to Clinical Translation

In summary, this study has successfully developed an intelligent CeO₂@NMN/SA aerogel dressing. It is far more than just a physical covering; it is a "micro-factory" that can actively sense and modulate the wound microenvironment. By coordinately scavenging ROS and replenishing NAD⁺, the dressing precisely activates the Sirt1-Nrf2/HO-1 pathway—a critical cellular protection and repair axis—thereby simultaneously addressing the four major challenges of diabetic wound healing: oxidative damage, inflammation, infection, and regenerative failure.

This work represents a significant breakthrough in the field of diabetic wound management. The materials are relatively safe, and the fabrication process is scalable, showcasing immense clinical potential. Future research will focus on optimizing large-scale manufacturing processes, conducting long-term biosafety evaluations, and validating its efficacy in large animal models, with the ultimate goal of translating this revolutionary technology from the lab to the clinic, offering hope to millions of diabetic patients worldwide.